RxDoctor Payments Data

Anthony Ippolito, DO

Rheumatology · Dover, NHNPI 1801012372

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 42 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $531 and has fallen 84.5% since, to $82 in 2021.

$706in general payments, 2019–2025

Across 42 payments — averaging $16.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$105
  • Lilly USA, LLC$96
  • Genentech USA, Inc.$64
  • Amgen$63
  • Pfizer$61
  • Novartis$57
  • plus $259 from 10 others

What the payments were for

  • Food & beverage$706100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$706 in reported general payments places this provider in the 65th percentile of 48 rheumatology providers in New Hampshire.

See all rheumatology providers in New Hampshire

Medicare billing

Part B allowed, 2024
$67,369
Medicare patients
405
Services billed
732

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Orencia ClickjectAbatacept63$350,072
Humira(Cf) PenAdalimumab39$343,721
StelaraUstekinumab15$252,978
Taltz AutoinjectorIxekizumab28$176,178
OrenciaAbatacept12$68,694
RinvoqUpadacitinib11$68,593
ForteoTeriparatide13$54,207
Teriparatide16$47,339
Hydroxychloroquine Sulfate180$5,661
MethotrexateMethotrexate Sodium183$4,667
Celecoxib150$4,068
Prednisone411$3,026
Colchicine17$1,859
Gabapentin72$1,271
Methylprednisolone47$837

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$25$252,97815 claims
E.r. Squibb & Sons, L.L.C.Orencia$13$68,69412 claims
AbbVieRinvoq$31$68,59311 claims
Lilly USA, LLCForteo$96$54,20713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 48 rheumatology providers in New Hampshire.

Other rheumatology in Dover

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →